Free Trial
LON:DPH

Dechra Pharmaceuticals (DPH) Share Price, News & Analysis

Dechra Pharmaceuticals logo

About Dechra Pharmaceuticals Stock (LON:DPH)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
3,866
3,866
52-Week Range
N/A
Volume
2.04 million shs
Average Volume
1.29 million shs
Market Capitalization
£4.40 billion
P/E Ratio
N/A
Dividend Yield
1.20%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Receive DPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DPH Stock News Headlines

Dechra Pharmaceuticals PLC (DPH.L)
Trump’s true trade war strategy
The media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada the 51st state because he’s desperate for critical minerals… They think his involvement in Ukraine is just another resource grab… They think his tariffs will wreck the economy… But they’re all missing the bigger picture.
Form 8.3 - Dechra Phartmaceuticals PLC - Amendment
Dechra Pharmaceuticals PLC DPH
See More Headlines

DPH Stock Analysis - Frequently Asked Questions

Shares of DPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dechra Pharmaceuticals investors own include 32Red (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Rolls-Royce Holdings plc (RR.L), Cranswick (CWK) and Drax Group (DRX).

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
Personal Services
Current Symbol
LON:DPH
CIK
N/A
Fax
N/A
Employees
2,457
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
1.42
Net Income
-£27.90 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£761.50 million
Price / Cash Flow
24.43
Book Value
GBX 663 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
£4.40 billion
Optionable
Not Optionable
Beta
0.78
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (LON:DPH) was last updated on 6/26/2025 by MarketBeat.com Staff
From Our Partners